SeaLife gets new funding for its antibiotic lead development


Based on the successful development in the first two years of SeaLife antibiotic lead program, the company gets follow up funding from The Austrian Research Promotion Agency (FFG). The fund support the pre-clinical development of SLP0904 the novel first-in class antibiotic against MRSA and vancomycin resistant enterococci (VRE) that should enter clinics in 2015.

< back